Novartis Wins Fda Approval For Leqvio On Second Try
Novartis Said Wednesday That The Fda Has Cleared Its Pcsk9-Targeting Sirna Leqvio (Inclisiran) As An Add-On Therapy To Help Decrease Cholesterol Levels In Certain High-Risk Adults. The Drug, Which Will Be Available In Early January, Is Indicated For Use Along With Maximally Tolerated Statins For Patients With Heterozygous Familial Hypercholesterolaemia (Hefh) Or Clinical Atherosclerotic Cardiovascular Disease (Ascvd) Who Require Additional Lowering Of Ldl Cholesterol."Leqvio Is A Revolutionary Approach
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!